252 related articles for article (PubMed ID: 25959529)
21. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
22. Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment.
Aigner E; Bachofner N; Klein K; De Geyter C; Hohla F; Patsch W; Datz C
J Clin Endocrinol Metab; 2009 Apr; 94(4):1229-35. PubMed ID: 19158194
[TBL] [Abstract][Full Text] [Related]
23. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone.
Wajcberg E; Sriwijitkamol A; Musi N; DeFronzo RA; Cersosimo E
J Clin Endocrinol Metab; 2007 Apr; 92(4):1256-62. PubMed ID: 17244785
[TBL] [Abstract][Full Text] [Related]
24. Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW.
Tripathy D; Clement SC; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Gastaldelli A; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Musi N; Reaven PD; DeFronzo RA
Diabetes Care; 2014 Jun; 37(6):1706-11. PubMed ID: 24705615
[TBL] [Abstract][Full Text] [Related]
25. Intramyocellular Ceramides: Subcellular Concentrations and Fractional De Novo Synthesis in Postabsorptive Humans.
Chung JO; Koutsari C; Blachnio-Zabielska AU; Hames KC; Jensen MD
Diabetes; 2017 Aug; 66(8):2082-2091. PubMed ID: 28483801
[TBL] [Abstract][Full Text] [Related]
26. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
Smith RC; Jin H; Li C; Bark N; Shekhar A; Dwivedi S; Mortiere C; Lohr J; Hu Q; Davis JM
Schizophr Res; 2013 Jan; 143(1):18-24. PubMed ID: 23200554
[TBL] [Abstract][Full Text] [Related]
27. Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome.
Herrmann BL; Saller B; Stratmann M; Berg C; Mann K; Janssen OE
Horm Metab Res; 2005 Jan; 37(1):49-52. PubMed ID: 15702440
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
[TBL] [Abstract][Full Text] [Related]
29. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
[TBL] [Abstract][Full Text] [Related]
30. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
31. Pioglitazone treatment enhances the sympathetic nervous system response to oral carbohydrate load in obese individuals with metabolic syndrome.
Straznicky NE; Grima MT; Sari CI; Eikelis N; Lambert GW; Nestel PJ; Richards K; Dixon JB; Schlaich MP; Lambert EA
Metabolism; 2015 Jul; 64(7):797-803. PubMed ID: 25827058
[TBL] [Abstract][Full Text] [Related]
32. Effects of pioglitazone and high-fat diet on ceramide metabolism in rat skeletal muscles.
Zendzian-Piotrowska M; Baranowski M; Zabielski P; Górski J
J Physiol Pharmacol; 2006 Nov; 57 Suppl 10():101-14. PubMed ID: 17242494
[TBL] [Abstract][Full Text] [Related]
33. Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
Krag MB; Nielsen S; Guo Z; Pedersen SB; Schmitz O; Christiansen JS; Jørgensen JO
Clin Endocrinol (Oxf); 2008 Sep; 69(3):452-61. PubMed ID: 18331610
[TBL] [Abstract][Full Text] [Related]
34. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
[TBL] [Abstract][Full Text] [Related]
36. Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.
Fujitaka K; Otani H; Jo F; Jo H; Nomura E; Iwasaki M; Nishikawa M; Iwasaka T
Endocr J; 2011; 58(6):425-32. PubMed ID: 21498915
[TBL] [Abstract][Full Text] [Related]
37. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
Bone HG; Lindsay R; McClung MR; Perez AT; Raanan MG; Spanheimer RG
J Clin Endocrinol Metab; 2013 Dec; 98(12):4691-701. PubMed ID: 24057294
[TBL] [Abstract][Full Text] [Related]
38. Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle.
Li W; Tonelli J; Kishore P; Owen R; Goodman E; Scherer PE; Hawkins M
Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1301-7. PubMed ID: 17213476
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
[TBL] [Abstract][Full Text] [Related]
40. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
